Literature DB >> 23065380

Effect of sinomenine on vascular smooth muscle cell dedifferentiation and neointima formation after vascular injury in mice.

Lihua Zhu1, Yarong Hao, Hongjing Guan, Changping Cui, Song Tian, Da Yang, Xinan Wang, Shuming Zhang, Lang Wang, Hong Jiang.   

Abstract

Sinomenine, a pure alkaloid extract from Sinomenium acutum, has anti-inflammatory and immunoregulatory functions. This study investigated the efficiency and the signalling pathways involved in the effect of sinomenine on vascular smooth muscle cell (VSMC) dedifferentiation in response to platelet-derived growth factor (PDGF)-BB stimulation and vascular injury. VSMCs were isolated from rat aorta and preincubated with sinomenine before being stimulated with PDGF-BB. WST and BrdU incorporation assays were used to evaluate VSMC proliferation. Flow cytometric analysis was performed for testing the cell cycle progression. The cell migration of VSMCs were analysed using a Transwell system. The expression of VSMC specific genes and signalling proteins were tested by Western blot. For the animal study, C57/BL6 mice were fed either normal rodent chow diets or sinomenine chow diets that supplemented with 0.09 % sinomenine (w/w) in the normal chows for 14 days before carotid artery wire injury. PDGF-BB activated the dedifferentiation of VSMCs characterised by decreased expression of SMA, Smoothelin and SM22α. However, sinomenine treatment preserved the dedifferentiation in response to PDGF-BB. The activations of mitogen-activated protein kinase extracellular signal-regulated kinases, Akt, GSK3β and STAT3 induced by PDGF-BB were also inhibited in sinomenine-treated VSMCs. In vivo evidence with wire-injured mice exhibited a reduction in neointimal area and an increase in smooth muscle-specific gene expression in the sinomenine-treated group. In this study, we found that sinomenine-suppressed VSMC phenotype switching induced by PDGF-BB in vitro and neointimal formation in vivo. Therefore, sinomenine is a potential candidate to be used in the treatment of vascular proliferative disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23065380     DOI: 10.1007/s11010-012-1474-9

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  31 in total

1.  The actin-binding protein Girdin and its Akt-mediated phosphorylation regulate neointima formation after vascular injury.

Authors:  Hiroshi Miyake; Kengo Maeda; Naoya Asai; Rei Shibata; Hitoshi Ichimiya; Mayu Isotani-Sakakibara; Yumiko Yamamura; Katsuhiro Kato; Atsushi Enomoto; Masahide Takahashi; Toyoaki Murohara
Journal:  Circ Res       Date:  2011-03-17       Impact factor: 17.367

Review 2.  Signaling mechanisms that regulate smooth muscle cell differentiation.

Authors:  Christopher P Mack
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-07       Impact factor: 8.311

3.  In vitro pharmacological actions of sinomenine on the smooth muscle and the endothelial cell activity in rat aorta.

Authors:  Seiichiro Nishida; Hiroyasu Satoh
Journal:  Life Sci       Date:  2006-03-27       Impact factor: 5.037

4.  Requirement for ERK activation in sinomenine-induced apoptosis of macrophages.

Authors:  Xiaobo He; Jianli Wang; Zhenhong Guo; Qiuyan Liu; Taoyong Chen; Xiaojian Wang; Xuetao Cao
Journal:  Immunol Lett       Date:  2004-11-25       Impact factor: 3.685

5.  Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity.

Authors:  Y Z Wang; W Wharton; R Garcia; A Kraker; R Jove; W J Pledger
Journal:  Oncogene       Date:  2000-04-20       Impact factor: 9.867

6.  Role of the JAK/STAT pathway in rat carotid artery remodeling after vascular injury.

Authors:  Y Seki; H Kai; R Shibata; T Nagata; H Yasukawa; A Yoshimura; T Imaizumi
Journal:  Circ Res       Date:  2000-07-07       Impact factor: 17.367

Review 7.  Immunosuppressive and anti-inflammatory activities of sinomenine.

Authors:  Quanxing Wang; Xiao-Kang Li
Journal:  Int Immunopharmacol       Date:  2010-11-23       Impact factor: 4.932

8.  Effect of sinomenine on antibody responses in mice.

Authors:  H Hojo; Y Kondo; H Umeda; T Tahira; Y Hashimoto
Journal:  J Immunopharmacol       Date:  1985

9.  Immunoregulatory effects of sinomenine on the T-bet/GATA-3 ratio and Th1/Th2 cytokine balance in the treatment of mesangial proliferative nephritis.

Authors:  Yue Cheng; Jingbo Zhang; Weiping Hou; Daihong Wang; Furong Li; Yaoquan Zhang; Fahuan Yuan
Journal:  Int Immunopharmacol       Date:  2009-03-29       Impact factor: 4.932

Review 10.  Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development.

Authors:  Hiroyuki Hao; Giulio Gabbiani; Marie-Luce Bochaton-Piallat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-08-07       Impact factor: 8.311

View more
  4 in total

1.  Sodium ferulate inhibits neointimal hyperplasia in rat balloon injury model.

Authors:  Jing Zhang; Jing Chen; Jian Yang; Changwu Xu; Jiawang Ding; Jun Yang; Qing Guo; Qi Hu; Hong Jiang
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

2.  Atorvastatin calcium inhibits phenotypic modulation of PDGF-BB-induced VSMCs via down-regulation the Akt signaling pathway.

Authors:  Shuang Chen; Baoqin Liu; Dehui Kong; Si Li; Chao Li; Huaqin Wang; Yingxian Sun
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

3.  Rosuvastatin suppresses platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferation and migration via the MAPK signaling pathway.

Authors:  Jianting Gan; Ping Li; Zhengdong Wang; Jian Chen; Xiangwen Liang; Ming Liu; Wenchao Xie; Ruixing Yin; Feng Huang
Journal:  Exp Ther Med       Date:  2013-08-20       Impact factor: 2.447

4.  Apatinib attenuates phenotypic switching of arterial smooth muscle cells in vascular remodelling by targeting the PDGF Receptor-β.

Authors:  Wenchao Shao; Xiaoguang Li; Jiangtong Peng; Siyuan Fan; Minglu Liang; Kai Huang
Journal:  J Cell Mol Med       Date:  2020-07-22       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.